← Leaderboards
Marcin Kortylewski
Beckman Research Institute/City Of Hope
$7,220,327
Attributed
$8,277,766
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $960K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,277,766 · 4
By mechanism
R01$8,277,766 · 4
Top collaborators
- Susanta K Hui3 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Jeffrey Y Wong$4,970,582
- Susanta K Hui$5,584,345
- Guido Marcucci$19,718,636
- Bin Zhang$2,891,856
- Hua E Yu$13,108,796
Others in their field
Top investigators on “Cell Death”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Gregory H Reaman · National Childhood Cancer Foundation$155,748,965
- David R. Weir · University Of Michigan At Ann Arbor$155,654,998
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- William George Nelson · Johns Hopkins University$85,651,800
Research focus
Cell DeathTumorMolecularCytotoxicSignal TransductionImmuneCellsMediatingDesignIn VivoBaseAgonistTranscription FactorOncogenicTherapeutic EffectIn Vivo ModelCancer CellLeukemiaNucleaseImmunotherapeutic AgentImmunogenicImmunotherapyClinically RelevantInnovation
Grant awards (18)
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia$715,641
R01 · FY2025 · CA · contact PI
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia$687,979
R01 · FY2024 · CA · contact PI
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia$711,258
R01 · FY2023 · CA · contact PI
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma$451,162
R01 · FY2022 · CA · contact PI
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma$456,635
R01 · FY2021 · CA · contact PI
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia$430,377
R01 · FY2021 · CA · contact PI
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma$460,943
R01 · FY2020 · CA · contact PI
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia$421,762
R01 · FY2020 · CA · contact PI
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma$428,676
R01 · FY2019 · CA · contact PI
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia$413,286
R01 · FY2019 · CA · contact PI
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma$529,603
R01 · FY2018 · CA · contact PI
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia$430,377
R01 · FY2018 · CA · contact PI
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia$428,441
R01 · FY2017 · CA · contact PI
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia$348,600
R01 · FY2015 · CA · contact PI
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia$338,142
R01 · FY2014 · CA · contact PI
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia$327,684
R01 · FY2013 · CA · contact PI
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia$348,600
R01 · FY2012 · CA · contact PI
CpG-siRNA Conjugates to Target Acute Myeloid Leukemia$348,600
R01 · FY2011 · CA · contact PI